onr:"swepub:oai:gup.ub.gu.se/251174"
Search: onr:"swepub:oai:gup.ub.gu.se/251174" > Treatment of acrome...
- 1 of 1
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04991naa a2200985 4500 | |
| 001 | oai:gup.ub.gu.se/251174 | |
| 003 | SwePub | |
| 008 | 240528s2000 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/2511742 URI |
| 024 | 7 | a https://doi.org/10.1056/NEJM2000042034216042 DOI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Trainer, P J4 aut |
| 245 | 1 0 | a Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. |
| 264 | 1 | c 2000 |
| 520 | a Patients with acromegaly are currently treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverse effects. Pegvisomant is a genetically engineered growth hormone-receptor antagonist that blocks the action of growth hormone.We conducted a 12-week, randomized, double-blind study of three daily doses of pegvisomant (10 mg, 15 mg, and 20 mg) and placebo, given subcutaneously, in 112 patients with acromegaly.The mean (+/-SD) serum concentration of insulin-like growth factor I (IGF-I) decreased from base line by 4.0+/-16.8 percent in the placebo group, 26.7+/-27.9 percent in the group that received 10 mg of pegvisomant per day, 50.1+/-26.7 percent in the group that received 15 mg of pegvisomant per day, and 62.5+/-21.3 percent in the group that received 20 mg of pegvisomant per day (P<0.001 for the comparison of each pegvisomant group with placebo), and the concentrations became normal in 10 percent, 54 percent, 81 percent, and 89 percent of patients, respectively (P<0.001 for each comparison with placebo). Among patients treated with 15 mg or 20 mg of pegvisomant per day, there were significant decreases in ring size, soft-tissue swelling, the degree of excessive perspiration, and fatigue. The score fortotal symptoms and signs of acromegaly decreased significantly in all groups receiving pegvisomant (P< or =0.05). The incidence of adverse effects was similar in all groups.On the basis of these preliminary results, treatment of patients who have acromegaly with a growth hormone-receptor antagonist results in a reduction in serum IGF-I concentrations and in clinical improvement. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
| 653 | a Acromegaly | |
| 653 | a blood | |
| 653 | a drug therapy | |
| 653 | a Adenoma | |
| 653 | a drug therapy | |
| 653 | a pathology | |
| 653 | a Adult | |
| 653 | a Autoantibodies | |
| 653 | a blood | |
| 653 | a Double-Blind Method | |
| 653 | a Female | |
| 653 | a Human Growth Hormone | |
| 653 | a adverse effects | |
| 653 | a analogs & derivatives | |
| 653 | a blood | |
| 653 | a immunology | |
| 653 | a therapeutic use | |
| 653 | a Humans | |
| 653 | a Insulin-Like Growth Factor I | |
| 653 | a metabolism | |
| 653 | a Male | |
| 653 | a Middle Aged | |
| 653 | a Pituitary Neoplasms | |
| 653 | a drug therapy | |
| 653 | a pathology | |
| 653 | a Receptors | |
| 653 | a Somatotropin | |
| 653 | a antagonists & inhibitors | |
| 700 | 1 | a Drake, W M4 aut |
| 700 | 1 | a Katznelson, L4 aut |
| 700 | 1 | a Freda, P U4 aut |
| 700 | 1 | a Herman-Bonert, V4 aut |
| 700 | 1 | a van der Lely, A J4 aut |
| 700 | 1 | a Dimaraki, E V4 aut |
| 700 | 1 | a Stewart, P M4 aut |
| 700 | 1 | a Friend, K E4 aut |
| 700 | 1 | a Vance, M L4 aut |
| 700 | 1 | a Besser, G M4 aut |
| 700 | 1 | a Scarlett, J A4 aut |
| 700 | 1 | a Thorner, M O4 aut |
| 700 | 1 | a Parkinson, C4 aut |
| 700 | 1 | a Klibanski, A4 aut |
| 700 | 1 | a Powell, J S4 aut |
| 700 | 1 | a Barkan, A L4 aut |
| 700 | 1 | a Sheppard, M C4 aut |
| 700 | 1 | a Malsonado, M4 aut |
| 700 | 1 | a Rose, D R4 aut |
| 700 | 1 | a Clemmons, D R4 aut |
| 700 | 1 | a Johannsson, Gudmundur,d 1960u Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för kroppssammansättning och metabolism,Institute of Internal Medicine, Dept of Body Composition and Metabolism4 aut0 (Swepub:gu)xjgudn |
| 700 | 1 | a Bengtsson, B A4 aut |
| 700 | 1 | a Stavrou, S4 aut |
| 700 | 1 | a Kleinberg, D L4 aut |
| 700 | 1 | a Cook, D M4 aut |
| 700 | 1 | a Phillips, L S4 aut |
| 700 | 1 | a Bidlingmaier, M4 aut |
| 700 | 1 | a Strasburger, C J4 aut |
| 700 | 1 | a Hackett, S4 aut |
| 700 | 1 | a Zib, K4 aut |
| 700 | 1 | a Bennett, W F4 aut |
| 700 | 1 | a Davis, R J4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för invärtesmedicin, Avdelningen för kroppssammansättning och metabolism4 org |
| 773 | 0 | t The New England journal of medicineg 342:16, s. 1171-7q 342:16<1171-7x 0028-4793 |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/251174 |
| 856 | 4 8 | u https://doi.org/10.1056/NEJM200004203421604 |
Find in a library
- The New England journal of medicine (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Trainer, P J
- Drake, W M
- Katznelson, L
- Freda, P U
- Herman-Bonert, V
- van der Lely, A ...
- show more...
- Dimaraki, E V
- Stewart, P M
- Friend, K E
- Vance, M L
- Besser, G M
- Scarlett, J A
- Thorner, M O
- Parkinson, C
- Klibanski, A
- Powell, J S
- Barkan, A L
- Sheppard, M C
- Malsonado, M
- Rose, D R
- Clemmons, D R
- Johannsson, Gudm ...
- Bengtsson, B A
- Stavrou, S
- Kleinberg, D L
- Cook, D M
- Phillips, L S
- Bidlingmaier, M
- Strasburger, C J
- Hackett, S
- Zib, K
- Bennett, W F
- Davis, R J
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Endocrinology an ...
- Articles in the publication
- The New England ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
